Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791876 | 0.79 | SLC2A1 (0.41) | SLC2A1BRD4 | |
| SCHEMBL23791868 | 0.79 | SLC2A1 (0.41) | SLC2A1BRD4 | |
| SCHEMBL23791873 | 0.79 | SLC2A1 (0.41) | SLC2A1BRD4 | |
| SCHEMBL23791678 | 0.76 | PGR (0.38) | — | |
| SCHEMBL21608391 | 0.74 | SLC2A1 (0.38) | SLC2A1BRD4 | |
| SCHEMBL21603477 | 0.74 | FPR2 (0.43) | — | |
| SCHEMBL31560788 | 0.73 | USP5 (0.40) | RXFP1 | |
| SCHEMBL21608578 | 0.73 | SLC2A1 (0.41) | SLC2A1BRD4SLC6A2 | |
| SCHEMBL21608521 | 0.72 | GRIN2B (0.38) | RXFP1 | |
| SCHEMBL25810956 | 0.72 | SLC2A1 (0.46) | SLC2A1BRD4ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | SLC2A1 861/4885BRD4 2664/4885SLC6A2 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.